Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
YTS-109 by Bristar Immunotech Biotechnology for Dermatomyositis: Likelihood of Approval
YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Dermatomyositis. According to GlobalData, Phase...
YTS-109 by Bristar Immunotech Biotechnology for Polymyositis: Likelihood of Approval
YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis. According to GlobalData, Phase...
YTS-109 by Bristar Immunotech Biotechnology for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval
YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA...